Edaravone oral - Treeway
Alternative Names: FAB-122; FNP-122; TW-001; TW-101Latest Information Update: 16 Jan 2024
At a glance
- Originator Treeway
- Developer Ferrer; Treeway
- Class Anti-ischaemics; Antidementias; Antihaemorrhagics; Antiparkinsonians; Hepatoprotectants; Neuroprotectants; Pyrazolones; Small molecules; Vascular disorder therapies
- Mechanism of Action Antioxidants; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Amyotrophic lateral sclerosis
- Phase II Alzheimer's disease
Most Recent Events
- 22 Feb 2024 Ferrer terminates the phase III ADOREXT trial in Amyotrophic lateral sclerosis in Spain, Italy, France, Belgium, Germany, the Netherlands, Poland, Ireland and Sweden due to lack of efficacy of Edaravone (NCT05866926) (EudraCT2022-003050-32)
- 10 Jan 2024 Safety and efficacy data from the phase III ADORE trial in Amyotrophic lateral sclerosis released by Ferrer
- 27 Aug 2023 TW 001 licensed to Specialised Therapeutics Asia in Australia and New Zealand